share_log

众生药业:控股子公司RAY1225注射液减重Ⅱ期临床试验获积极结果

Gelonghui Finance ·  Nov 20, 2024 10:24

格隆汇11月20日|众生药业公告,控股子公司众生睿创的一类创新多肽药物RAY1225注射液用于超重/肥胖患者的Ⅱ期临床试验获得子研究顶线分析数据。初步结果显示,RAY1225注射液在中国成人超重/肥胖参与者中表现出积极的疗效和良好的安全性,试验结果理想,达到预期目的。RAY1225注射液是众生睿创研发的、具有全球自主知识产权的创新结构多肽药物,属于长效GLP-1类药物,具有GLP-1受体和GIP受体双重激动活性。

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 353

Recommended

Write a comment

Statement

This page is machine-translated. Moomoo tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.